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endograft
William D. Jordan Jr, MD, Joshua Rovin, MD, Sina Moainie,
MD, Joseph Bavaria, MD, Richard Cambria, MD, Mark
Fillinger, MD,William McMillan, MD, Jon S. Matsumura, MD
Objective: As thoracic aortic aneurysms (TAAs) are more
frequently being treated with endografts, the anatomic
challenges of the thoracic aorta have led to design mod-
iﬁcations of endografts. The Conformable GORE TAG (CTAG)
device (W. L. Gore & Associates, Flagstaff, Ariz) was spe-
ciﬁcally designed to be more conformable in tortuous
anatomy, more resistant to compression, and more
accommodating to various aortic diameters compared with
the original GORE TAG device. This prospective, multicenter
study evaluated the safety and effectiveness of the CTAG
endograft in the repair of descending TAA.
Methods: This was a prospective, multicenter regulatory
study with a primary end point of freedom from major
device event through 1 month after treatment. Two-year
outcomes included aneurysm-related morbidity (endoleaks
and morphology changes), aneurysm-related mortality, and
all-cause mortality.
Results: Fifty-one patients were enrolled between October
2009 and October 2010, with at least one endograft
implanted in 50 patients. After the regulatory study suc-
cessfully completed its primary end point and expanded to a
continued-access phase, 15 additional patients were enrolled
in the continued-access arm of the study from February 2011
until September 2011, for a total treatment group of 66
patients for the early results and 65 patients for the long-
term clinical results with imaging evaluation. There was one
30-day death (1.5%), two patients (3%) with spinal cord
ischemia, and two central strokes (3%) 30 days. Five
patients (7.6%) died 1 year; one of ascending aortic
aneurysm rupture, two of cardiac disease, and two of respi-
ratory failure. The core laboratory adjudicated 1-month
imaging in 60 patients (92.3%), where nine endoleaks (15.0%)
were identiﬁed (one type Ia, four type II, and four inde-
terminate). Forty-ﬁve patients (69.2%) had 2-year imaging
with ﬁve endoleaks (11.1%; two type II and three inde-
terminate), and one patient had a distal aortic dilatation that
required a secondary intervention. At 2 years, 20 of 38
imaged patients (52.6%) had aneurysm shrinkage5mm, 15
(39.5%) had no change in diameter, and three patients (7.9%)
had an increase in aneurysm diameter of5mm.There were
no conversions, fractures, compressions, or aneurysm rup-
tures of the treated segment through 2 years.*Full articles available online at www.jvascsurg.org
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http://dx.doi.org/10.1016/S1078-5884(15)00085-4Conclusions: This next-generation thoracic endograft has a
low rate of major device events through 2 years, with no
graft compressions or device failures. The data for this new
endograft demonstrate favorable outcomes and conﬁrm
low risks for treatment for patients with TAA. Follow-up will
be continued for 5 years.Cost analysis of endovascular versus open repair in the
treatment of thoracic aortic aneurysms
Jacob R. Gillen, MD, Basil W. Schaheen, MD, Kenan W.
Yount, MD, MBA, Kenneth J. Cherry, MD, John A. Kern, MD,
Irving L. Kron, MD, Gilbert R. Upchurch Jr, MD, Christine L.
Lau, MD, MBA
Objective: For descending thoracic aortic aneurysms (TAAs),
it is generally considered that thoracic endovascular aortic
repairs (TEVARs) reduce operative morbidity and mortality
compared with open surgical repair. However, long-term
differences in survival of patients have not been demon-
strated, and an increased need for aortic reintervention has
been observed. Many assume that TEVAR becomes less
cost-effective through time because of higher rates of
reintervention and surveillance imaging. This study inves-
tigated midterm outcomes and hospital costs of TEVAR
compared with open TAA repair.
Methods: This was a retrospective, single-institution review
of elective TAA repairs between 2005 and 2012. Patient
demographics, operative outcomes, reintervention rates,
and hospital costs were assessed. The literature was also
reviewed to determine commonly observed complication
and reintervention rates for TEVAR and open repair. Monte
Carlo simulation was used to model and to forecast hospital
costs for TEVAR and open TAA repair up to 3 years after
intervention.
Results: Our cohort consisted of 131 TEVARs and 27 open
repairs. TEVAR patients were signiﬁcantly older (67.2 vs 58.7
years old; P = .02) and trended toward a more severe
comorbidity proﬁle. Operative mortality for TEVAR and
open repair was 5.3% and 3.7%, respectively (P = 1.0). There
was a trend toward more complications in the TEVAR group,
although not statistically signiﬁcant (all P > .05). In-hospital
costs were signiﬁcantly greater in the TEVAR group ($52,008
vs $37,172; P = .001). However, cost modeling by use of
reported complication and reintervention rates from the
literature overlaid with our cost data produced a higher cost
for the open group in-hospital ($55,109 vs $48,006) and at 3
years ($58,426 vs $52,825). Interestingly, TEVAR hospital
costs, not reintervention rates, were the most signiﬁcant
driver of cost in the TEVAR group.
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lower mortality and complication rates with open TAA
repair, with signiﬁcantly lower costs within this cohort
compared with TEVAR. These ﬁndings were likely, at least in
part, to be due to the milder comorbidity proﬁle of these
patients. In contrast, cost modeling by Monte Carlo simu-
lation demonstrated lower costs with TEVAR compared with
open repair at all time points up to 3 years after inter-
vention. Our institutional data show that with appropriate
selection of patients, open repair can be performed safely
with low complication rates comparable to those of TEVAR.
The cost model argues that despite the costs associated
with more frequent surveillance imaging and reinterven-
tions, TEVAR remains the more cost-effective option even
years after TAA repair.Durability and survival are similar after elective
endovascular and open repair of abdominal aortic
aneurysms in younger patients
Kevin Lee, MD, Elaine Tang, Luc Dubois, MD, MSc, Adam H.
Power, MPhil (Cantab), Guy DeRose MD, Thomas L. Forbes,
MD
Objective: The role of endovascular repair (EVAR) of aortic
aneurysms in young patients is controversial. The purpose
of this study was to determine the long-term outcomes and
reintervention rates in patients 60 years of age or younger
who underwent elective open or endovascular repair of an
abdominal aortic aneurysm.
Methods: Retrospective review of a prospectively collected
vascular surgery database at a university-afﬁliated medical
center was performed to identify all patients who under-
went elective repair of an abdominal aortic aneurysm
between 2000 and 2013 and were 60 years of age or
younger at the time of the repair. Preoperative anatomic
measurements were performed and compared with
instructions for use (IFU) criteria for the endografts.
Results: The study cohort comprised 169 patients 60 years
of age or younger (mean age, 56.7  2.8 years) who
underwent elective repair (119 open repair, 50 EVAR).
Patients treated with open repair and EVAR had similar
comorbidities, except that EVAR patients were more likely
to have hypertension (P = .03) and poor left ventricular
function (P = .04). The open repair group had signiﬁcantly
larger suprarenal (P = .004) and infrarenal (P = .005) neck
angles, shorter neck lengths (P< .001), and larger maximum
aneurysm diameter (P = .02) compared with the EVAR
group. Only ﬁve patients (13%) in the EVAR group did not
meet all IFU criteria. The overall in-hospital mortality rate
was 1.8% (0% EVAR, 2.5% open repair; P = .56). Overall
mean life expectancy was 11.5 years (9.8 years EVAR, 11.9
years open repair; P = .09). The 1-year (98% EVAR, 96%
open repair), 5-year (86% EVAR, 88% open repair), and 10-
year (54% EVAR, 75% open repair) survival did not differ
between EVAR and open repair (P = .16). Long-term survival
(78% EVAR, 85% open repair; P = .09) and reintervention
rates (12% EVAR, 16% open repair; P = .80) did not differ.No late aneurysm rupture or aneurysm-related deaths were
observed. The most common causes of long-term mortality
were malignant disease and cardiovascular events. Rein-
terventions in the open repair group were exclusively lap-
arotomy related (incisional hernia repairs), whereas all
reinterventions in the EVAR group were aortic related,
including one conversion to open repair.
Conclusions: After elective aneurysm repair, younger
patients have a moderate life expectancy related to malig-
nant disease and cardiovascular health. EVAR offers dura-
bility and long-term survival similar to those with open
repair in these younger patients as long as aneurysm
anatomy and IFU are adhered to.Abdominal compartment syndrome associated with
endovascular and open repair of ruptured abdominal
aortic aneurysms
Chen Rubenstein, MD, Gabriel Bietz, MBChB, Daniel L.
Davenport, PhD, Michael Winkler, MD, Eric D. Endean, MD
Background: Abdominal compartment syndrome (ACS) is a
known complication of ruptured abdominal aortic aneur-
ysm (rAAA) repair and can occur with either endovascular
(EVAR) or open repair. We hypothesize that the underlying
mechanism for the development of ACS may differ for
patients treated with EVAR or open operation.
Methods: All patients who presented with rAAA at a ter-
tiary care medical center between January 2005 and
December 2010 were included in the study. Demographic
factors, type of repair (open vs EVAR), development of ACS,
intraoperative and postoperative ﬂuid requirements, esti-
mated blood loss, length of stay, and morbidity and mor-
tality were recorded. Student t-test and Fisher exact test
were performed. A P value < .05 was considered signiﬁcant.
Results: Seventy-three patients, 62 men and 11 women
with an average age of 70.5 years, were treated for rAAA.
Forty-four (60%) underwent open repair; 29 (40%) had
EVAR. Overall mortality was 42% (31 of 73), with mortality
being 31% (9 of 29) in EVAR and 48% (21 of 44) in open
repair. ACS developed in 21 patients (29%), more frequently
in open repair than in EVAR (15 of 44 [34%] vs 6 of 29
[21%]; P = NS). Mortality was higher in patients who
developed ACS compared with those without ACS (13 of 21
[62%] vs 17 of 52 [33%]; P = .022). This ﬁnding was espe-
cially pronounced in the EVAR group, in which mortality in
patients with ACS was 83% (5 of 6) compared with 17% (4
of 23) without ACS (P = .005). Intraoperative ﬂuid require-
ments were signiﬁcantly higher in EVAR patients who
developed ACS compared with those without ACS, including
packed red blood cells (5600 mL vs 1100 mL; P < .0001),
total blood products (9300 mL vs 1500 mL; P < .001),
crystalloid (11,200 mL vs 4500 mL; P < .001), and estimated
blood loss (5000 mL vs 660 mL; P = .006). In patients treated
with open repair, there were no signiﬁcant differences in
intraoperative ﬂuid requirements between those who
developed ACS and those without ACS. However, patients
who developed ACS after open repair required signiﬁcantly
360 Abstractsmore crystalloid on the ﬁrst and second postoperative days
(ﬁrst postoperative day, 8300 mL vs 5600 mL [P = .01];
second postoperative day, 6500 mL vs 3800 mL [P = .004]).
Conclusions: This study demonstrates that the development
of ACS after repair of rAAA is associated with increased
mortality, especially in EVAR-treated patients. The higher
intraoperative blood and blood product requirements
associated with ACS in EVAR patients suggest that one
potential cause of early ACS is continued hemorrhage from
lumbar and inferior mesenteric vessels through the rup-
tured aneurysm sac. Hence, open ligation of such vessels
should be considered in patients developing early ACS after
EVAR for rAAA.Revascularization of asymptomatic carotid stenosis is not
appropriate in patients on dialysis
Theodore H. Yuo, MD, MS, Joseph Sidaoui, MD, Luke K.
Marone, MD, Michel S. Makaroun, MD, Rabih A. Chaer, MD,
MS
Objective: Outcomes of carotid endarterectomy (CEA) or
carotid angioplasty and stenting (CAS) for asymptomatic
disease in patients on dialysis are not well characterized,
with questionable stroke prevention and survival. This study
reports outcomes of carotid revascularization in asympto-
matic dialysis patients in the United States.
Methods: Using United States Renal Data System (USRDS)
databases, we identiﬁed all dialysis patients who underwent
CEA or CAS for asymptomatic disease from 2005 to 2008.
CEA and CAS were identiﬁed by Current Procedural Termi-
nology (American Medical Association, Chicago, Ill) codes,
and symptom status and comorbidities by International
Classiﬁcation of Diseases-9th Revision, Clinical Modiﬁcation
codes. Primary outcomes were stroke, cardiac complica-
tions, and death at 30 days and at 1 and 3 years. Predictors
of death were identiﬁed using multivariate regression
models.
Results: Of 738,561 dialysis patients, 2131 asymptomatic
patients underwent carotid revascularization (1805 CEA,
326 CAS). The mortality rate was 4.7% at 30 days (4.6% CEA,
4.9% CAS; P = .807). Kaplan-Meier estimates of survival
were 75.1% at 1 year (75.9% CEA, 70.7% CAS) and 43.4% at
3 years (43.7% CEA, 41.6% CAS). The stroke rate was 6.5% at
30 days (6.4% CEA, 6.9% CAS; P = .774) and 13.6% at 1 year
(13.3% CEA, 15.0% CAS; P = .490). Cardiac complications
occurred in 22.0% of patients (3.3% myocardial infarction)
at 30 days (22.2% CEA, 20.6% CAS; P = .525). The combined
stroke or death rate was 10.2% at 30 days (10.1% CEA,
10.9% CAS; P = .490) and 33.5% at 1 year (32.2% CEA, 39.6%
CAS; P = .025). Age >70 years at the time of surgery and
increased time on dialysis were predictive of death,
whereas a history of renal transplant was a protective
factor.
Conclusions: Patients on dialysis have high perioperative
and long-term stroke or death rates after CEA or CAS for
asymptomatic stenosis, with a median survival that is less
than recommended by current guidelines. As a result,carotid intervention in these patients appears to be
inappropriate.Total laparoscopic bypass is safe and effective for
aortoiliac occlusive disease
Kaoutar Ghammad, MD, Arnaud Dupuis, MD, Laurent
Amond, MD, Christine D’Hont, MD, Edo Wijtenburg, MD,
Philippe Piette, MD, Philippe Remy, MD
Objective: We reviewed our experience of total laparo-
scopic aortic bypass surgery performed for aortoiliac
occlusive disease (AIOD), focusing on early 30-day mortality
and morbidity and short-term and midterm outcomes.
Methods: A monocentric retrospective study was con-
ducted between October 2002 and October 2011; we per-
formed 173 total laparoscopic aortic surgeries to treat
AIOD.
Results: Patients included 135 men and 38 women. The
mean age was 57.2 years (range, 34-77 years). The median
operative time was 205 minutes (range, 120-420 minutes),
the median aortic clamping time was 50 minutes (range, 20-
120 minutes), and the mean blood loss was 263 mL (range,
0-3200 mL). Conversion to open surgery was necessary in
12.1% of patients. The 30-day postoperative mortality rate
was 2.3% (four of 173 patients). Major morbidity occurred
in 6.9% of patients. Wound complications occurred in 8%.
Four patients had a groin infection (2.3%), treated by sur-
gical trimming in three patients and replacement of the
prosthesis by venous bypass in one patient. Early graft
thrombosis (within 30 days) occurred in one patient (0.6%),
requiring reintervention. With a mean follow-up of 42
months (standard deviation, 37 months), 96% of bypasses
were patent. Patency rates at 3 and 5 years were 97% and
85% respectively.
Conclusions: In selected patients, laparoscopic aortic bypass
surgery for AIOD is a safe procedure with an acceptable
morbidity rate, short intensive care unit and hospital stay,
fast recovery, and early return to general diet. It is a good
indication after failure of endovascular surgery.Randomized controlled trial comparing the safety and
efﬁcacy between the FUSION BIOLINE heparin-coated
vascular graft and the standard expanded
polytetraﬂuoroethylene graft for femoropopliteal bypass
Alan B. Lumsden, MD, Nicholas J. Morrissey, MD
Objective: Despite improvements in endovascular therapy
for lower extremity arterial disease, open surgical revascu-
larization is still required when the disease is extensive.
Although autogenous vein is the conduit of choice for open
femoropopliteal bypass, prosthetic grafts can be an
acceptable alternative when adequate vein is not available.
The FUSION BIOLINE heparin-coated vascular graft (Maquet
Endovascular, Wayne, NJ) was developed to improve the
patency rate associated with standard prosthetic grafts. The
current study, the FINEST Trial (Comparison of Safety and
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Coated Vascular Graft and EXXCEL Soft ePTFE), was
designed to assess the clinical outcome of heparin-coated
and standard vascular grafts in a prospective, randomized,
controlled, multicenter trial.
Methods: During a 25-month period ending in June 2012,
209 eligible patients scheduled to undergo elective pros-
thetic femoral to above-knee or below-knee popliteal
bypass were randomized to receive a standard expanded
polytetraﬂuoroethylene (ePTFE) graft or the heparin-coated
FUSION BIOLINE vascular graft. Among 203 patients in the
efﬁcacy analysis, claudication was the presenting symptom
in 147 (72.4%), and the site of the distal anastomosis was at
the above-knee level in 174 (85.7%). Grafts were assessed
by duplex ultrasound imaging and ankle-brachial indices
performed postoperatively at discharge and at 30 days, 6
months, and 12 months. The primary efﬁcacy end point was
primary patency of the study graft. The primary safety end
point was the composite of major adverse events and
periprocedural death. Secondary end points included the
time to hemostasis of bleeding at the anastomotic suture
hole and primary assisted and secondary patency.
Results: The primary patency rates at 6 months were 86.4%
for the FUSION BIOLINE heparin-coated vascular graft group
compared with 70.0% for the standard ePTFE group, a dif-
ference of 16.4% (95% conﬁdence interval, 2.7%-29.9%; P =
.006), and the respective rates at 12 months were 76.5%
and 67.0% (95% conﬁdence interval, 4.8% to 23.0%; P =
.05). The mean time to hemostasis of bleeding at the suture
hole was 3.5 minutes in the FUSION BIOLINE group and 11.0
minutes in the standard ePTFE group (P < .0001). Major
adverse events were signiﬁcantly lower in the FUSION
BIOLINE group, occurring in 17.1%, compared with 30.7% in
the standard ePTFE group (P = .033), principally a result of a
lower rate of major graft reinterventions through 12
months in the FUSION BIOLINE group (16.2% vs 30.7%).
Conclusions: Data from this randomized multicenter study
demonstrated improved midterm patency, less bleeding at
the suture hole, and lower major adverse events with the
FUSION BIOLINE heparin-coated vascular graft compared
with standard ePTFE grafts. Although the ultimate long-
term beneﬁt of the graft cannot be ascertained with the
data currently available, the utility of the FUSION BIOLINE
vascular graft appears promising.Technique and results of femoral bifurcation
endarterectomy by eversion
Julie Dufranc, MD, Laura Palcau, MD, Maxime Heyndrickx,
MD, Djelloul Gouicem, MD, Olivier Cofﬁn, MD, Aurélien
Felisaz, MD, Ludovic Berger, MD, PhDObjective: This study evaluated, in a contemporary pro-
spective series, the safety and efﬁcacy of femoral endar-
terectomy using the eversion technique and compared our
results with results obtained in the literature for the
standard endarterectomy with patch closure.
Methods: Between 2010 and 2012, 121 patients (76% male;
mean age, 68.7 years; diabetes, 28%; renal insufﬁciency,
20%) underwent 147 consecutive femoral bifurcation
endarterectomies using the eversion technique, associating
or not inﬂow or outﬂow concomitant revascularization. The
indications were claudication in 89 procedures (60%) and
critical limb ischemia in 58 (40%). Primary, primary assisted,
and secondary patency of the femoral bifurcation, clinical
improvement, limb salvage, and survival were assessed
using Kaplan-Meier life-table analysis. Factors associated
with those primary end-points were evaluated with uni-
variate analysis.
Results: The technical success of eversion was of 93.2%.
The 30-day mortality was 0%, and the complication rate
was 8.2%; of which, half were local and benign. Median
follow-up was 16 months (range, 1.6-31.2 months). Pri-
mary, primary assisted, and secondary patencies were,
respectively, 93.2%, 97.2%, and 98.6% at 2 years. Primary,
primary assisted, and secondary maintenance of clinical
improvement were, respectively, 79.9%, 94.6%, and 98.6%
at 2 years. The predictive factors for clinical degradation
were clinical stage (Rutherford category 5 or 6, P = .024),
platelet aggregation inhibitor treatment other than clo-
pidogrel (P = .005), malnutrition (P = .025), and bad tibial
runoff (P = .0016). A reintervention was necessary in
18.3% of limbs at 2 years: 2% involving femoral bifurca-
tion, 6.1% inﬂow improvement, and 9.5% outﬂow
improvement. The risk factors of reintervention were
platelet aggregation inhibitor (other than clopidogrel, P ¼
.049) and cancer (P ¼ .011). Limb preservation at 2 years
was 100% in the claudicant population. Limb salvage was
88.6% in the critical limb ischemia population, with a
statistically higher rate for patients with malnutrition (P ¼
.029), preoperative platelet count >450 109/L (P ¼
.0071), platelet aggregation inhibitor treatment other
than clopidogrel (P ¼ .022), preoperative deep femoral
artery occlusion or stenosis >75% (P ¼ .0064), and poor
tibial runoff (P ¼ .00042).
Conclusions: Eversion femoral bifurcation endarterectomy
is a safe, efﬁcient, and reproducible technique for the
treatment of atherosclerotic femoral lesions. Advantages
are notable, especially the lack of need for prosthetic
angioplasty, eliminating the risk of patch infection or
pseudoaneurysms and permitting direct puncture if endo-
vascular procedures are needed for assisted patency.
